BACKGROUND: In previous studies, maternal exposure to folic acid antagonists was associated with increased risks of neural tube defects, cardiovascular defects, oral clefts and urinary tract defects. The objective of the current study was to assess the possible effects of using folic acid antagonists in pregnancy on placenta-mediated adverse outcomes of pregnancy. METHODS: We used data from an administrative database to retrospectively compare the occurrence of placenta-mediated adverse pregnancy outcomes between pregnant women exposed to folic acid antagonists and women without exposure to these agents. RESULTS: We included in the analysis a total of 14 982 women who had been exposed to folic acid antagonists and 59 825 women who had not been exposed. Sulfamethoxazole-trimethoprim was the most frequently prescribed dihydrofolate reductase inhibitor (a total of 12 546 exposures during the preconception period and all 3 trimesters), and phenobarbital was the most frequently prescribed among the other folic acid antagonists (a total of 1565 exposures). The risks of preeclampsia (adjusted odds ratio [OR] 1.52, 95% confidence interval [CI] 1.39-1.66), severe preeclampsia (OR 1.77, 95% CI 1.38-2.28), placental abruption (OR 1.32, 95% CI 1.12-1.57), fetal growth restriction defined as less than the 10th percentile (OR 1.07, 95% CI 1.01-1.13), fetal growth restriction defined as less than the 3rd percentile (OR 1.22, 95% CI 1.11-1.34) and fetal death (OR 1.35, 95% CI 1.07-1.70) were greater among mothers with exposure to folic acid antagonists. In general, the risks associated with exposure to other folic acid antagonists were higher than those associated with exposure to dihydrofolate reductase inhibitors. Supplementary analyses involving tight matching with propensity score, restriction of the analysis to women with exposure during the first and second trimesters and restriction of the analysis to specific categories of folic acid antagonists yielded similar results. INTERPRETATION: Maternal exposure to folic acid antagonists appears to increase the risk of placenta-mediated adverse outcomes of pregnancy.
BACKGROUND: In previous studies, maternal exposure to folic acid antagonists was associated with increased risks of neural tube defects, cardiovascular defects, oral clefts and urinary tract defects. The objective of the current study was to assess the possible effects of using folic acid antagonists in pregnancy on placenta-mediated adverse outcomes of pregnancy. METHODS: We used data from an administrative database to retrospectively compare the occurrence of placenta-mediated adverse pregnancy outcomes between pregnant women exposed to folic acid antagonists and women without exposure to these agents. RESULTS: We included in the analysis a total of 14 982 women who had been exposed to folic acid antagonists and 59 825 women who had not been exposed. Sulfamethoxazole-trimethoprim was the most frequently prescribed dihydrofolate reductase inhibitor (a total of 12 546 exposures during the preconception period and all 3 trimesters), and phenobarbital was the most frequently prescribed among the other folic acid antagonists (a total of 1565 exposures). The risks of preeclampsia (adjusted odds ratio [OR] 1.52, 95% confidence interval [CI] 1.39-1.66), severe preeclampsia (OR 1.77, 95% CI 1.38-2.28), placental abruption (OR 1.32, 95% CI 1.12-1.57), fetal growth restriction defined as less than the 10th percentile (OR 1.07, 95% CI 1.01-1.13), fetal growth restriction defined as less than the 3rd percentile (OR 1.22, 95% CI 1.11-1.34) and fetal death (OR 1.35, 95% CI 1.07-1.70) were greater among mothers with exposure to folic acid antagonists. In general, the risks associated with exposure to other folic acid antagonists were higher than those associated with exposure to dihydrofolate reductase inhibitors. Supplementary analyses involving tight matching with propensity score, restriction of the analysis to women with exposure during the first and second trimesters and restriction of the analysis to specific categories of folic acid antagonists yielded similar results. INTERPRETATION: Maternal exposure to folic acid antagonists appears to increase the risk of placenta-mediated adverse outcomes of pregnancy.
Authors: I M Graham; L E Daly; H M Refsum; K Robinson; L E Brattström; P M Ueland; R J Palma-Reis; G H Boers; R G Sheahan; B Israelsson; C S Uiterwaal; R Meleady; D McMaster; P Verhoef; J Witteman; P Rubba; H Bellet; J C Wautrecht; H W de Valk; A C Sales Lúis; F M Parrot-Rouland; K S Tan; I Higgins; D Garcon; G Andria Journal: JAMA Date: 1997-06-11 Impact factor: 56.272
Authors: S M Schwartz; D S Siscovick; M R Malinow; F R Rosendaal; R K Beverly; D L Hess; B M Psaty; W T Longstreth; T D Koepsell; T E Raghunathan; P H Reitsma Journal: Circulation Date: 1997-07-15 Impact factor: 29.690
Authors: Shi Wu Wen; Xi-Kuan Chen; Marc Rodger; Ruth Rennicks White; Qiuying Yang; Graeme N Smith; Ronald J Sigal; Sherry L Perkins; Mark C Walker Journal: Am J Obstet Gynecol Date: 2008-01 Impact factor: 8.661
Authors: Jennifer J Adibi; Alexander J Layden; Rahel L Birru; Alexandra Miragaia; Xiaoshuang Xun; Megan C Smith; Qing Yin; Marisa E Millenson; Thomas G O'Connor; Emily S Barrett; Nathaniel W Snyder; Shyamal Peddada; Rod T Mitchell Journal: Hum Reprod Update Date: 2021-06-22 Impact factor: 15.610
Authors: Rebecca Lipsitz; Susan Garges; Rosemarie Aurigemma; Prasith Baccam; David D Blaney; Allen C Cheng; Bart J Currie; David Dance; Jay E Gee; Joseph Larsen; Direk Limmathurotsakul; Meredith G Morrow; Robert Norton; Elizabeth O'Mara; Sharon J Peacock; Nicki Pesik; L Paige Rogers; Herbert P Schweizer; Ivo Steinmetz; Gladys Tan; Patrick Tan; W Joost Wiersinga; Vanaporn Wuthiekanun; Theresa L Smith Journal: Emerg Infect Dis Date: 2012-12 Impact factor: 6.883
Authors: Shi Wu Wen; Josee Champagne; Ruth Rennicks White; Doug Coyle; William Fraser; Graeme Smith; Dean Fergusson; Mark C Walker Journal: J Pregnancy Date: 2013-11-18
Authors: Renata Bortolus; Fenneke Blom; Francesca Filippini; Mireille N M van Poppel; Emanuele Leoncini; Denhard J de Smit; Pier Paolo Benetollo; Martina C Cornel; Hermien E K de Walle; Pierpaolo Mastroiacovo Journal: BMC Pregnancy Childbirth Date: 2014-05-13 Impact factor: 3.007